Feasibility of apalutamide combined with androgen deprivation therapy and short-course low-dose prednisone in treating metastatic hormone-sensitive prostate cancer: a pilot randomized controlled trial

IntroductionThe role of prednisone in the prevention of androgen receptor antagonist-related rash and treatment for metastatic hormone-sensitive prostate cancer (mHSPC) is unclear. This pilot trial (ChiCTR2200060388) aimed to investigate the feasibility of apalutamide combined with androgen deprivat...

Ful tanımlama

Detaylı Bibliyografya

Asıl Yazarlar:	Dingyuan Yang, Wenqiang Chen, Fei Lai, Mingxing Qiu, Jun Li
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	Frontiers Media S.A. 2023-11-01
Seri Bilgileri:	Frontiers in Oncology
Konular:	apalutamide metastatic hormone-sensitive prostate cancer prednisone randomized controlled trial rash
Online Erişim:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1110807/full
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!